The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
Summary: Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been approved for the treatment of hormone receptor-positive breast cancer. In this study, we use murine syngeneic tumor models and in vitro assays to investigate the impact of abemaciclib on T cells, the t...
Main Authors: | David A. Schaer, Richard P. Beckmann, Jack A. Dempsey, Lysiane Huber, Amelie Forest, Nelusha Amaladas, Yanxia Li, Ying Cindy Wang, Erik R. Rasmussen, Darin Chin, Andrew Capen, Carmine Carpenito, Kirk A. Staschke, Linda A. Chung, Lacey M. Litchfield, Farhana F. Merzoug, Xueqian Gong, Philip W. Iversen, Sean Buchanan, Alfonso de Dios, Ruslan D. Novosiadly, Michael Kalos |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-03-01
|
Series: | Cell Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124718302341 |
Similar Items
-
Efficiency and tolerability of abemaciclib in elderly patients
by: E. I. Kovalenko, et al.
Published: (2020-12-01) -
The role of abemaciclib in treatment of advanced breast cancer
by: Amelia McCartney, et al.
Published: (2018-05-01) -
High-content molecular profiling of T-cell therapy in oncology
by: Ruslan Novosiadly, et al.
Published: (2016-01-01) -
Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
by: Claudia Omarini, et al.
Published: (2020-08-01) -
Profile of abemaciclib and its potential in the treatment of breast cancer
by: Martin JM, et al.
Published: (2018-08-01)